Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017422 | 0.88 | THRB (0.48) | GPR119THRBMAPTKDM4EGAA | |
| SCHEMBL16827765 | 0.87 | MAPT (0.47) | GPR119THRBMAPTKDM4EGAA | |
| SCHEMBL29918474 | 0.84 | GPR119 (0.50) | GPR119THRBMAPTKDM4EGAA | |
| SCHEMBL5453963 | 0.80 | KDM4E (0.49) | GPR119THRBMAPTKDM4EGAA | |
| SCHEMBL7606781 | 0.80 | KDM4E (0.49) | GPR119THRBMAPTKDM4EGAA | |
| SCHEMBL8007100 | 0.80 | GPR119 (0.47) | GPR119THRBMAPTKDM4EMEN1 | |
| SCHEMBL18176188 | 0.79 | POLB (0.59) | GPR119THRBMAPTMEN1KMT2A | |
| SCHEMBL18169251 | 0.78 | TRPV3 (0.41) | GPR119THRBMAPTKDM4EGAA | |
| SCHEMBL16828054 | 0.78 | GPR119 (0.59) | GPR119THRBMAPTGAASMN1; SMN2 | |
| SCHEMBL12539635 | 0.77 | PDE4B (0.47) | GPR119THRBMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | GPR119 502/4885THRB 1490/4885MAPT 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.